Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing

被引:4
|
作者
Cheng, Xiaolin [1 ]
Gu, Zhangyuan [1 ]
Sun, Xiaoyin [1 ]
Zhuang, Zhigang [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai First Matern & Infant Hosp, Dept Breast Surg, Shanghai 201204, Peoples R China
关键词
Genetic counseling (GC); genetic testing (GT); hereditary breast cancer; Chinese; questionnaire; GERMLINE MUTATIONS; PANEL; SUSCEPTIBILITY; PREVALENCE; FAMILIES; BRCA2; WOMEN;
D O I
10.21037/tcr.2019.11.43
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In recent years, genetic testing (GT) has developed rapidly in China. However, the cancer genetic service system is still immature in China. Little is known about the opinions around genetic counseling (GC) and GT in Chinese individuals at high risk of breast cancer. This work aims to understand the changes in awareness, attitudes, and willingness of high-risk populations before and after GT, as well as the possible barriers to GC/GT. Methods: Several questionnaires for the high-risk populations of breast cancer were completed. Then, some patients were selected for free single/multi-gene testing as well as further survey and statistical analysis. Results: Despite low levels of awareness, Chinese high-risk breast cancer groups hold positive attitudes about GC/GT. There were differences in the willingness of different groups of high-risk people. After GT, different testing results led to different views and choices for the patients than before GT. Lack of genetic knowledge of breast cancer, misunderstanding, cost, fear of adverse effects, and policy market factors are obstacles to accepting GC/GT for the participants. Conclusions: Chinese doctors need to communicate according to the specific situation of high-risk individuals in pre-test counseling and post-test counseling. The national policy and GT market also need to be improved to support the hereditary breast cancer families' follow-up service system.
引用
收藏
页码:2893 / 2905
页数:13
相关论文
共 50 条
  • [41] Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design
    Chiara L. Blomen
    Aliaksandra Pott
    Alexander E. Volk
    Lars Budäus
    Isabell Witzel
    Scientific Reports, 11
  • [42] Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions
    Su, Yifan
    Yao, Qianlan
    Xu, Yuyin
    Yu, Chengli
    Zhang, Jing
    Wang, Qian
    Li, Jiwei
    Shi, Di
    Yu, Baohua
    Zeng, Yupeng
    Zhu, Xiaoli
    Bai, Qianming
    Zhou, Xiaoyan
    FRONTIERS IN GENETICS, 2021, 12
  • [43] The presence of micrometastases before and after high-dose therapy in high-risk Stage II breast cancer patients.
    Kvalheim, G
    Erikstein, B
    Holte, H
    Hervik, I
    Gilen, E
    Sommer, H
    Anker, G
    Telhaug, R
    Kolstad, A
    Nesland, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S148 - S148
  • [44] Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers
    Clark, Nina M.
    Roberts, Emma A.
    Fedorenko, Catherine
    Sun, Qin
    Dubard-Gault, Marianne
    Handford, Cynthia
    Yung, Rachel
    Cheng, Heather H.
    Sham, Jonathan G.
    Norquist, Barbara M.
    Flanagan, Meghan R.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (03) : 1312 - 1326
  • [45] Genetic counseling and testing in endometrial cancer: Are we capturing high-risk women?
    Lee, Jessica
    Gubernick, Lindsay
    Chern, Jing-Yi
    Gerber, Deanna
    Blank, Stephanie V.
    Pothuri, Bhavana
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers
    Nina M. Clark
    Emma A. Roberts
    Catherine Fedorenko
    Qin Sun
    Marianne Dubard-Gault
    Cynthia Handford
    Rachel Yung
    Heather H. Cheng
    Jonathan G. Sham
    Barbara M. Norquist
    Meghan R. Flanagan
    Annals of Surgical Oncology, 2023, 30 (3) : 1312 - 1326
  • [47] Factors that influence genetic testing outcomes in high-risk breast/ovarian families.
    Herold, CI
    Goldfeder, KL
    Tigges, J
    Stopfer, JE
    Weber, BL
    Domchek, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 865S - 865S
  • [49] Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer
    Larsen, Finn Ole
    Markussen, Alice
    Jensen, Benny V.
    Fromm, Anne L.
    Vistisen, Kirsten K.
    Parner, Vibeke K.
    Linnemann, Dorte
    Hansen, Rasmus H.
    Johannesen, Helle H.
    Schou, Jakob V.
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E7 - E14
  • [50] A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy
    Humphrey, Clare
    Millard, Trish Ann
    Brenin, Christiana
    Dhakal, Ajay
    Falkson, Carla Isadora
    Petroni, Gina R.
    Wages, Nolan
    Dillon, Patrick Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)